

January 03, 2023

BSE Limited
P. J. Towers, Dalal Street,
Mumbai-400 001

National Stock Exchange of India Ltd.
Exchange Plaza, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai-400 051

Scrip ID-540025

Scrip Code-ADVENZYMES

Dear Sir/Madam,

**Re: Update on acquisition of 50% stake in Saiganesh Enzytech Solutions Private Limited;
and an additional 4.83% of JC Biotech Private Limited (existing 85% subsidiary)**

Further to our letter dated November 11, 2022, we would like to inform that the Company has completed the acquisition of the following:

- 1) 50% stake in Saiganesh Enzytech Solutions Private Limited (CIN: U01100MP2022PTC063261) ["**SESPL**"] by way of subscription to the issue of 19,991,663 Equity shares of SESPL on private placement/preferential issue basis, at a total consideration of Rs. 59,974,989
- 2) Additional stake of 4.83% of JC Biotech Private Limited (existing 85% subsidiary) (CIN: U65993TG1991PTC013624) ["**JCB**"] by way of purchase of 1,000,000 Equity shares from one of the existing shareholder of JCB at a total consideration of Rs.68,000,000. Post completion of transfer of said shares, the shareholding of the Company in JCB has increased to 89.83% of paid-up share capital of JCB.

Kindly take the same on record.

Thanking you,
Yours faithfully,
For Advanced Enzyme Technologies Limited

Sanjay Basantani
Company Secretary and Head – Legal